Gain Therapeutics Inc (NAS:GANX)
$ 2.35 -0.15 (-6%) Market Cap: 42.42 Mil Enterprise Value: 33.36 Mil PE Ratio: 0 PB Ratio: 4.90 GF Score: 57/100

Gain Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 08:30PM GMT
Release Date Price: $4.85 (-0.21%)
Jamie Cohen
Jefferies - Analyst

Good afternoon, and welcome to the Jefferies Global Healthcare Conference. My name is Jamie Cohen with Jefferies Investment Banking. And it is my great pleasure to welcome Matthias Alder from Gain Therapeutics.

Matthias Alder
Gain Therapeutics, Inc. - CEO

Thank you, Jamie. And thanks to Jefferies for organizing this conference and giving us the opportunity to present the exciting story that we have at Gain Therapeutics. So Gain is a computational drug discovery company that is leading the discovery and development of allosteric small molecule therapies. That's a very compact, condensed statement and I'll unpack that for you over the next 20 minutes or so.

We're a public publicly-traded company. So I will be making forward-looking statements. So consider risk factors in our SEC filings before making investment decisions.

Gain has essentially three areas that drive value for the company and our stakeholders. The first area is the SEE-Tx drug discovery platform. It's AI and physics-based. I'll go a bit more in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot